Page results
-
Christmas is an exciting time even if it will be a bit different for us all this year. We might be spending more time inside, making us less active than usual for this time of year. However, it is still a good time to relax and enjoy some Christmas treats.
-
This page explains what patient-initiated follow-up (PIFU) involves after your treatment for endometrial (uterine or womb) cancer.
-
On Saturday 25 June 2022, UCLH partnered with North Middlesex University Hospital and Whittington Health to run a summer sickle cell event at Tottenham Hotspur Stadium for children and young people with sickle cell disorder.
-
Information about the Therapeutic Plasma Exchange at NHNN for patients, carers, and families.
-
The NHS has become the first healthcare system in the world to provide a new blood group genotyping test which is set to transform care for patients living with sickle cell disorder and thalassaemia.
-
This page explains the Rafaelo™ procedure, a treatment for haemorrhoids, which are also known as piles.
-
Trial of T-cell therapy for lung cancer begins at UCLH
-
Having proton beam therapy under general anaesthetic: information for children aged 1- 4 patient information.
-
Having proton beam therapy under general anaesthetic: information for children aged 5-8 patient information
-
UCLH is the first NHS trust to pilot a personalised educational package for patients living with stroke.
File results
-
FOI/2024/0097 - Laboratory Information Management System (LIMS)/ pathology IT system
-
FOI/2024/0101 - Immunoglobulin drug treatments
-
FOI/2024/0108 - Clinical letters/ EPR, PAS, patient portal systems, hybrid mail contract
-
FOI/2024/0112 - Fertility treatment in 2021
-
FOI/2024/0116 - Patient treatment due to noise levels of the London Underground
-
FOI/2024/0121 - Migraine treatments
-
FOI/2024/0126 - Ophthalmology RTT pathway
-
FOI/2024/0128 - Post mortem cardiac device interrogation
-
FOI/2024/0129 - Nursing associate and anaesthesia associate staffing
-
FOI/2024/0131 - Alpha-1 Proteinase-Inhibitor (AAT) purchased in 2023